贲门癌中巨噬细胞移动抑制因子表达与患者临床病理特征及预后的关系
DOI: 10.3971/j.issn.1000-8578.2016.09.010
Keywords: Partial Versus Radical Nephrectomy,Upper Gastrointestinal Carcinomas Incidence from 2003 to 2012 in Cixian, Hebei Province,Prognostic Value of Circulating Tumor Cells for Metastatic Prostate Cancer: A Metaanalysis,Correlation of CD68+ Tumor-associated Macrophages Number with Ki-67 Expression and Prognosis of Patients with Primary Hepatocellular Carcinoma,Advance of Prognostic Markers of Cervical Cancer,Metaplastic Carcinoma of Breast with Mesenchymal Differentiation: 28 Cases Report,Predictive Value of C-reactive Protein/Albumin Ratio on Prognosis of Patients with Primary Hepatocellular Carcinoma,Clinical Investigation on Qingfei Mixture Combined with Chemotherapy on Middle and Advanced Non-small Cell Lung Cancer,Expression and Clinical Significance of Artemin Protein in Triple-negative and Nontriple-negative Breast Cancer Tissues,Prognosis Factors for Patients with Stage pT3N0M0 Thoracic Esophageal Squamous Cell Carcinoma after Radical Resection,Value of 21-gene Assay in Treatment Decisions for Hormone Receptor-positive Nodepositive Early Breast Cancer
Abstract:
摘要 目的 探讨巨噬细胞移动抑制因子（macrophage migration inhibitory factor, MIF）在贲门癌中的表达及其与患者临床病理特征和预后的关系。方法 选取滨州医学院附属医院胸外科2008年1月—2009年12月经胸手术切除的贲门癌石蜡标本73例，采用免疫组织化学法检测贲门癌组织中MIF的表达水平，根据免疫反应强弱将其分为高表达组和低表达组，分析MIF表达水平与患者临床病理特征的关系，Kaplan-Meier生存曲线比较MIF高表达组和低表达组患者的生存期，Cox回归模型分析MIF的表达水平与临床病理特征及患者预后的关系。 结果 MIF在贲门癌组织中高表达42例，高表达率为57.5%。MIF表达水平与患者的年龄、性别、肿瘤分化程度、淋巴结转移和TNM分期无关（P>0.05），与肿瘤的浸润深度有关（P=0.025）。MIF高表达组和低表达组的生存期用Kaplan-Meier方法评估，并用Logrank检验进行比较，两组之间生存率差异有统计学意义（P=0.001）。多因素Cox回归模型分析表明，淋巴结转移（P=0.025）、MIF表达水平（P=0.001）是影响贲门癌预后的独立危险因素。结论 MIF的表达异常可能在贲门癌的浸润及预后中有重要作用，对患者预后的判断有一定指导意义
Full-Text
